Document Detail

Fluoxetine in depressed patients with renal failure and in depressed patients with normal kidney function.
MedLine Citation:
PMID:  8666216     Owner:  NLM     Status:  MEDLINE    
Nine depressed patients with normal kidney function and seven depressed patients with renal failure undergoing hemodialysis were treated with open-label fluoxetine 20 mg/day in an 8-week study. The study was designed to evaluate the pharmacokinetics of fluoxetine during repeated administration and to acquire preliminary data regarding the effectiveness of this antidepressant in a population undergoing hemodialysis. Six patients in each group completed the study. Of these, five patients undergoing hemodialysis and five patients with normal renal function experienced moderate to marked improvement in their depression. Side effects were equal and minor in both groups, indicating that fluoxetine is safe in patients with renal impairment. The mean +/- standard deviation steady-state plasma concentrations of the sum of fluoxetine plus its metabolite norfluoxetine for patients completing 8 weeks (N = 6, both groups) were comparable for the patients undergoing hemodialysis (253 +/- 61 ng/ml) and those with normal kidney function (218 +/- 122 ng/ml; t = 1.5, df = 70, p > 0.13). These data suggest that the efficacy of fluoxetine in patients with renal failure undergoing hemodialysis is comparable to that in patients with normal kidney function. These data further suggest that renal failure and the process of hemodialysis do not materially alter the pharmacokinetics of fluoxetine or its major metabolite norfluoxetine.
N B Levy; M Blumenfield; C M Beasley; A K Dubey; R J Solomon; R Todd; A Goodman; R R Bergstrom
Related Documents :
15930806 - Cardiovascular risk factors in hemodialysis patients: results from baseline data of kal...
18182806 - The mpo study: just a european hemo study or something very different?
7752506 - The efficacy of indomethacin in the treatment of uremic pericarditis.
12227726 - Arterial hypertension and left ventricular hypertrophy in hemodialysis patients.
22917916 - Major white matter fiber changes in medically intractable neocortical epilepsy in child...
16983596 - Early clinical experience with cardiocard - a credit card-sized electronic patient record.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  General hospital psychiatry     Volume:  18     ISSN:  0163-8343     ISO Abbreviation:  Gen Hosp Psychiatry     Publication Date:  1996 Jan 
Date Detail:
Created Date:  1996-08-08     Completed Date:  1996-08-08     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  7905527     Medline TA:  Gen Hosp Psychiatry     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  8-13     Citation Subset:  IM    
Department of Psychiatry and Medicine, Westchester County Medical Center, Valhalla, NY, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antidepressive Agents, Second-Generation / administration & dosage,  adverse effects,  pharmacokinetics*
Depressive Disorder / blood*,  drug therapy,  psychology
Dose-Response Relationship, Drug
Fluoxetine / administration & dosage,  adverse effects,  pharmacokinetics*
Kidney Failure, Chronic / blood*,  drug therapy,  psychology
Kidney Function Tests*
Metabolic Clearance Rate / physiology
Middle Aged
Personality Inventory
Renal Dialysis
Treatment Outcome
Reg. No./Substance:
0/Antidepressive Agents, Second-Generation; 54910-89-3/Fluoxetine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Depression in patients with coronary heart disease. A 12-month follow-up.
Next Document:  A new mechanism of mutation in man: expansion of trinucleotide repeats